Article Text

Download PDFPDF
Review: maximum androgen blockade does not confer additional survival benefit to androgen suppression in prostate cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In men with prostate cancer, is maximum androgen blockade (MAB) better than androgen suppression (AS) alone for prolonging survival?

Data sources

Studies were identified by searching computerised databases, trial registers, meeting abstracts, and reference lists and by contacting investigators and pharmaceutical companies.

Study selection

Studies were selected if they were randomised trials that began before 1991 and compared MAB (AS plus an antiandrogen, such as nilutamide, flutamide, or cyproterone acetate) with AS alone and if the treatment was given for ≥1 year.

Data extraction

Information was requested for each patient on stage of disease, age at randomisation, date of randomisation, treatment allocation, date of last follow up, date of death, and cause of death.

Main results

1 trials …

View Full Text


  • Sources of funding: Netherlands Cancer Institute; Imperial Cancer Research Fund; UK Medical Research Council; European Union.

  • For correspondence: PCTCG Secretariat, Biometrics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Cx Amsterdam, the Netherlands. Fax +31 20 617 2625.